{"Welcome.html": {"id": "Welcome.html", "text": "Welcome", "displayed_text": "Welcome"}, "Task.html": {"id": "Task.html", "text": "Task", "displayed_text": "Task"}, "ChangeTypes.html": {"id": "ChangeTypes.html", "text": "ChangeTypes", "displayed_text": "ChangeTypes"}, "Consent.html": {"id": "Consent.html", "text": "Consent", "displayed_text": "Consent"}, "Navigation.html": {"id": "Navigation.html", "text": "Navigation", "displayed_text": "Navigation"}, "Medicine_tweet_142": {"DOI": "10.1073/pnas.1515528113", "id": "Medicine_tweet_142", "News Finding": "Cost-effectiveness of #hpv #vaccines: ", "Paper Finding": "Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine.", "News Context": "Cost-effectiveness of #hpv #vaccines: ", "Paper Context": "Because of interstate migration and the long duration between HPV infection and resultant cervical cancer, much of the benefit of vaccination will be realized beyond a state's borders. Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine. Both of these vaccines are highly efficacious against HPV-16 and HPV-18 and are partially efficacious against other non-vaccine-targeted oncogenic serotypes .", "scores": "[1.0, 4.0, 5.0, 4.0, 4.0]", "field": "Medicine", "split": "train", "final_score": 4.0, "source": "tweets", "News URL": "722389929796304896", "text": "REPORTED FINDING: Cost-effectiveness of #hpv #vaccines: <br>PAPER FINDING: Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine.", "displayed_text": "REPORTED FINDING: Cost-effectiveness of #hpv #vaccines: <br>PAPER FINDING: Therefore, both cervical cancer incidence and expenditure can be substantially reduced if the states coordinate policies to promote expansion of coverage, particularly for the new nonavalent vaccine."}, "Medicine_tweet_6": {"DOI": "10.1038/s41467-018-08278-4", "id": "Medicine_tweet_6", "News Finding": "Ken Muneoka and colleagues @username find that BMP9 treatment promotes joint regeneration from digit amputation wounds.\n\n", "Paper Finding": "We show here that Bmp9 is transiently expressed during digit joint cavitation and that BMP9 treatment stimulates joint regeneration.", "News Context": "Ken Muneoka and colleagues @username find that BMP9 treatment promotes joint regeneration from digit amputation wounds.\n\n", "Paper Context": "Unlike other BMP family members, BMP9 is not effected by BMP antagonists such as Noggin 12 which suppresses BMP signaling and is necessary for joint morphogenesis . We show here that Bmp9 is transiently expressed during digit joint cavitation and that BMP9 treatment stimulates joint regeneration. During angiogenesis, BMP9 acts in a contextdependent manner, inhibiting neovascularization in a model of age-related macular degeneration , while stimulating angiogenesis associated with induced osteogenesis .", "scores": "[4.0, 5.0, 1.0, 4.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 5.0, "source": "tweets", "News URL": "1095638718826926080", "text": "REPORTED FINDING: Ken Muneoka and colleagues @username find that BMP9 treatment promotes joint regeneration from digit amputation wounds.\n\n<br>PAPER FINDING: We show here that Bmp9 is transiently expressed during digit joint cavitation and that BMP9 treatment stimulates joint regeneration.", "displayed_text": "REPORTED FINDING: Ken Muneoka and colleagues @username find that BMP9 treatment promotes joint regeneration from digit amputation wounds.\n\n<br>PAPER FINDING: We show here that Bmp9 is transiently expressed during digit joint cavitation and that BMP9 treatment stimulates joint regeneration."}, "Medicine_tweet_0": {"DOI": "10.1001/jama.2018.20578", "id": "Medicine_tweet_0", "News Finding": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Finding": "Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding.", "News Context": "This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  ", "Paper Context": "The median age of trial participants was 62 years (range, 53-74), 77 501 (47%) were men, 30 361 (19%) had diabetes, and the median baseline risk of the primary cardiovascular outcome was 9.2% (range, 2.6%-15.9%). Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding. This information may inform discussions with patients about aspirin for primary prevention of cardiovascular events and bleeding.", "scores": "[5.0, 5.0, 5.0, 5.0]", "field": "Medicine", "split": "train", "final_score": 5.0, "source": "tweets", "News URL": "1087877579288297472", "text": "REPORTED FINDING: This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  <br>PAPER FINDING: Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding.", "displayed_text": "REPORTED FINDING: This meta-analysis confirms that use of #aspirin for primary prevention of #cardiovasculardisease is associated with a lower risk of CV events including CV mortality and nonfatal AMI and #stroke, and an increased risk of major bleeding.  <br>PAPER FINDING: Aspirin use was associated with significant reductions in the composite cardiovascular outcome compared with no aspirin (57.1 per 10 000 participant-years with aspirin and 61.4 per 10 000 participant-years with no aspirin) (hazard ratio CONCLUSIONS AND RELEVANCE The use of aspirin in individuals without cardiovascular disease was associated with a lower risk of cardiovascular events and an increased risk of major bleeding."}, "Experience.html": {"id": "Experience.html", "text": "Experience", "displayed_text": "Experience"}, "End.html": {"id": "End.html", "text": "End", "displayed_text": "End"}}